Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Ferrari

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignanciesJutta Deckert, Marie-Cécile Wetzel, Laura M Bartle, et al.
Protein Science : a Publication of the Protein Society|September 12, 2014
Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactionsAaron Moulin, Magali Mathieu, Catherine Lawrence, et al.
Nature Medicine|September 11, 2019
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patientsAntonino Cassotta, Vincent Mikol, Thomas Bertrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial TumorsStéphanie Decary, Pierre-François Berne, Céline Nicolazzi, et al.
Journal of Medicinal Chemistry|October 7, 2011
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperoneFrançois Vallée, Chantal Carrez, Fabienne Pilorge, et al.
Glia|November 15, 2017
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse modelsMartine Latta-Mahieu, Bradford Elmer, Alexis Bretteville, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignanciesJutta Deckert, Marie-Cécile Wetzel, Laura M Bartle, et al.
Protein Science : a Publication of the Protein Society|September 12, 2014
Structures of a pan-specific antagonist antibody complexed to different isoforms of TGFβ reveal structural plasticity of antibody-antigen interactionsAaron Moulin, Magali Mathieu, Catherine Lawrence, et al.
Nature Medicine|September 11, 2019
A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patientsAntonino Cassotta, Vincent Mikol, Thomas Bertrand, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial TumorsStéphanie Decary, Pierre-François Berne, Céline Nicolazzi, et al.
Journal of Medicinal Chemistry|October 7, 2011
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperoneFrançois Vallée, Chantal Carrez, Fabienne Pilorge, et al.
Glia|November 15, 2017
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse modelsMartine Latta-Mahieu, Bradford Elmer, Alexis Bretteville, et al.
Nature Cancer|February 5, 2022
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulationLan Wu, Edward Seung, Ling Xu, et al.
Pageof 5